A 5-year-old boy received CD34-positive HLA haploidentical bone marrow transplantation from his father as treatment for refractory advanced neuroblastoma. He had residual disease in the para-aortic lymph nodes and multiple bones after the transplant. However, all of his residual disease had disappeared completely 3 years later. He developed grade I acute graft-versus-host disease (GVHD) but had no symptoms of chronic GVHD or any other complications. This case demonstrates the possibility of a graft-versus-tumor effect against neuroblastoma by HLA-mismatched allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation (2003) 32, 103-106. doi:10.1038/sj.bmt.1704070 Keywords: neuroblastoma; CD34; graft-versus-tumor
The therapeutic effect of donor lymphocyte infusion (DLI) for relapsed CML after allogeneic bone marrow transplantation (BMT) has been established, 1 and the immunotherapeutic aspect of allogeneic hematopoietic stem cell transplantation (HSCT) has recently been emphasized, especially since the introduction of a reduced-intensity preparative regimen followed by allogeneic HSCT. Successful nonmyeloablative allogeneic PBSCT for metastatic renal cell carcinoma was reported by Childs et al. 2 Although similar trials have been ongoing for many kinds of solid tumors, 3 a graft-versus-tumor (GVT) effect against neuroblastoma (NBL) has not been reported. We describe a patient with refractory advanced NBL who showed tumor regression over 3 years after allogeneic SCT, despite persistent metastatic lesions after SCT. This is the first case suggesting a GVT effect in neuroblastoma.
Case report
A 4-year-old boy was diagnosed with stage 4 NBL (INSS: international neuroblastoma staging system) involving his right adrenal gland, multiple para-aortic lymph nodes, bone marrow and multiple bones in April 1997. Tumor markers were abnormally elevated at the diagnosis. Urinary vanillymandelic acid (VMA) and homovanillic acid (HVA) were 313.6 (upper limit 16.0) and 251.0 (upper limit 35.0) mg/mg creatinine, respectively. Serum neuron-specific enolase (NSE) was beyond the range of measurement (41000 ng/ml, upper limit 10.0). The response for induction chemotherapy (modified A1: 4 vincristine, cyclophosphamide, pirarubicin and cisplatin, CPT-11) was partial and double megatherapy was performed ( Figure 1 ) according to our strategy. The first megatherapy, consisting of ifosfamide (12.5 g/m 2 ) and LPAM (210 mg/m 2 ) followed by autologous CD34-positive BM cell rescue, was given in November 1997. CD34-positive cells were collected by the Isolex system (NEXELL, Deerfield, IL, USA) and cryopreserved during repeated first-line chemotherapy aimed at purging of tumor cells. Extirpation of the primary tumor with ipsilateral nephrectomy and biopsy of the para-aortic lymph nodes and a bone marrow were carried out after the first megatherapy in December 1997. Viable NBL cells were found histologically in the resected tumor, sampled lymph nodes and a bone specimen. Prognostic evaluations of the resected tumors were as follows. The characteristics were unfavorable histology according to Shimada's system, diploid and a single copy of N-myc. However, these evaluations were not carried out at the diagnosis, and the findings may have been be modified with chemotherapy. Urinary VMA was still elevated as 44.6 mg/mg creatinine 3 weeks after the surgery, and imaging techniques revealed remaining metastatic para-aortic lymph nodes and multiple bone lesions. Owing to its mild myelosuppression and effectiveness, we administered CPT-11 postoperatively.
As we could not harvest autologous hematopoietic stem cells for the second graft, we decided to perform an allogeneic HSCT. An HLA-matched donor was not available, so his HLA haplo-identical father was chosen as the donor. The conditioning regimen consisted of TBI /l on day 47 and reticulocytes reached 1% on day 33. Complete chimerism was confirmed by HLA typing of peripheral blood on day 42. The patient developed grade I acute GVHD (skin: stage 1). Skin biopsy was performed and histological findings were compatible with GVHD. Acute GVHD was well controlled by a short course of methylprednisolone and tacrolimus was discontinued at day 140, without any recurrence of GVHD thereafter. No other complication was observed.
Following transplant the patient still had persistent disease with elevated urinary VMA (24.6 mg/mg creatinine 80 days after the second transplant). The patient received additional conventional dose chemotherapy (CPT-11 and cyclophosphamide+pirarubicin) after the second transplant. However, conventional chemotherapy did not influence the urinary level of VMA, and the residual disease was still detected by imaging evaluation. Therefore, we decided to change our plan from curative therapy to supportive care to maintain quality of life (QOL). Contrary to our expectations, urinary VMA normalized and paraaortic lymph nodes were not detected by imaging techniques 18 months after the second transplant. Abnormal MIBG uptake imaging of multiple bones had disappeared at three years after allogeneic SCT (Figure 2) . The patient has been well for more than 4 years after the second transplant and there has been no sign of relapse.
Discussion
The prognosis of advanced NBL is extremely poor. Although intensive therapy with autologous BMT has improved the outcome of advanced NBL, disease-free survival of the patients with metastatic disease remains around 50%. 5 We have performed double megatherapy for these high-risk patients, 6 and recently we have started allo-graft for patients for whom sufficient autologous stem cells are not available. In this case where no matched donor was available, we elected to use CD34-positive progenitor cell transplantation from an HLA haplo-identical parent. CD34-positive progenitor cell transplantations from an HLA haplo-identical parent have been performed safely and the rate of GVHD or other complications is comparable to unrelated cord blood stem cell transplantation. 7, 8 In our experience, patients who had residual disease after the first autologous BMT tend to relapse after the second autograft. This case is therefore of interest as he has maintained CR up to 4 years post-transplant although he did not respond immediately after the allogeneic transplant. Allogeneic transplant as immunotherapy has received attention especially since the introduction of reducedintensity preparative regimens and nonmyeloablative transplant in recent years. Childs Graft-versus-tumor effect in advanced neuroblastoma M Inoue et al metastatic renal cell carcinoma regressed in 10 patients out of 19 after nonmyeloablative allogeneic PBSCT. Regression of metastases was delayed, occurring at a median of 129 days after transplantation and often followed the withdrawal of immunosuppressive agent. They concluded that these results are consistent with a GVT effect. This experience is consistent with our patient's clinical course. There have been no previous reports of a GVT response in NBL. Negrier et al 9 reported immunotherapy using autologous LAK cells and interleukin 2 for advanced NBL without significant clinical response. 9 Matthay et al 10 reported a CCG pilot study of allogeneic vs autologous purged BMT for NBL. They found no advantage of allogeneic transplant in their report. Although a GVT effect in NBL so far has not been reported, we demonstrate here the interesting clinical course of a patient who shows a strong possibility of a graft-versus-NBL effect. We therefore propose that allogeneic transplant for advanced NBL should be considered in the setting of a well-designed clinical study to clarify the immunological effect on NBL.
